Clinical Trial Update: Expanded Access to CD34+ Selection Utilizing Miltenyi CliniMACS Prodigy® for Patients Receiving Peripheral Blood Stem Cell Transplantations and Stem Cell Boosts

View source ↗

Summary

This clinical trial update describes expanded access to CD34+ selection using the Miltenyi CliniMACS Prodigy for patients receiving peripheral blood stem cell t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Combined Immunodeficiency
• Dyskeratosis Congenita
• Fanconi Anemia
• Sickle Cell Disease

Drugs mentioned

• Miltenyi CliniMACS Prodigy

Snippet

Sponsor: University of Florida | Conditions: Severe Combined Immunodeficiency, Fanconi Anemia | Status: AVAILABLE